The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2025
Filed:
Dec. 30, 2024
Applicant:
Abelzeta Inc., Rockville, MD (US);
Inventors:
Yihong Yao, Rockville, MD (US);
Jiaqi Huang, Rockville, MD (US);
Shigui Zhu, Rockville, MD (US);
Xin Yao, Rockville, MD (US);
Xiaobing Luo, Rockville, MD (US);
Yutian Wei, Rockville, MD (US);
Assignee:
ABELZETA INC., Rockville, MD (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4215 (2025.01); A61K 40/4221 (2025.01); A61K 40/4224 (2025.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); A61P 37/06 (2018.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C12N 5/0636 (2013.01); A61K 2239/13 (2023.05); A61K 2239/21 (2023.05); A61K 2239/22 (2023.05); A61K 2239/29 (2023.05); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01);
Abstract
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.